A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer.

Publication Type:

Journal Article


Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, Volume 14, Issue 6, p.836-45 (2011)


2011, Center-Authored Paper, October 2011, Public Health Sciences Division


Bevacizumab is approved for treatment of advanced non-small cell lung cancer (NSCLC) in combination with chemotherapy based on a 2-month median survival benefit demonstrated in one randomized trial. The cost-utility of adding bevacizumab to chemotherapy in advanced NSCLC remains unknown. We evaluated the cost-utility of bevacizumab added to chemotherapy in patients with advanced NSCLC.